期刊
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE
卷 19, 期 1, 页码 174-178出版社
KOREAN COLL NEUROPSYCHOPHARMACOLOGY
DOI: 10.9758/cpn.2021.19.1.174
关键词
Cariprazine; Clozapine; Effectiveness; Efficacy; Schizophrenia; Tolerability
Cariprazine is a novel antipsychotic drug that has shown clinical efficacy in treating schizophrenia, bipolar disorder, and Major Depressive Disorder. It can also be used as an adjunctive treatment in drug-resistant MDD patients. Combination therapy with cariprazine has shown benefits for patients with treatment-resistant schizophrenia, even improving adverse metabolic effects of other medications like clozapine.
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D-2/D-3 receptors with preferential binding to the D-3 receptor, antagonism of 5HT(2B) receptors, and partial agonism of 5HT(1A). Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据